Genor Biopharma plans major acquisition, reverse takeover

Genor Biopharma Holdings Limited has announced a proposed merger involving a very substantial acquisition, connected transaction, and reverse takeover. The transaction entails the issue of consideration shares under a specific mandate, a new listing application, and an application for a whitewash waiver. Key elements also include a special deal related to the retention plan for shareholder personnel.

In conjunction with these strategic moves, the company proposes a change of its name, an increase in its authorized share capital, and the adoption of a one-off share option plan. The despatch of a circular containing detailed information on these matters, including the Whitewash Waiver and the Retention Plan, is scheduled for Friday, December 5, 2025.

Shareholders and potential investors are cautioned that the merger closing is contingent upon the fulfillment or waiver of merger conditions precedent. This includes the approval of the new listing application by the Stock Exchange's listing committee and the granting of the whitewash waiver by the Executive, emphasizing the conditional nature of the proposed merger.